Current Status of Ketamine and Related Compounds for Depression

Experimental Therapeutics and Pathophysiology, National Institute of Mental Health (NIMH), 베서스다, Maryland, United States
The Journal of Clinical Psychiatry (Impact Factor: 5.81). 05/2013; 74(5):516-7. DOI: 10.4088/JCP.13ac08382
Source: PubMed
  • [Show abstract] [Hide abstract]
    ABSTRACT: While stressful experiences are a part of everyone's life, they can also exact a major toll on health. Stressful life experiences are associated with increased substance abuse, and there exists significant co-morbidity between mental illness and substance use disorders [N.D. Volkow & T.K. Li (2004) Nat. Rev. Neurosci., 5, 963–970; G. Koob & M.J. Kreek (2007) Am. J. Psych., 164, 1149–1159; R. Sinha (2008) Annals N.Y. Acad. Sci., 1141, 105–130]. The risk for development of mood or anxiety disorders after stress is positively associated with the risk for substance use disorders [R. Sinha (2008) Annals N.Y. Acad. Sci., 1141, 105–130], suggesting that there are common substrates for vulnerability to addictive and affective disorders. Understanding the molecular and physiological substrates of stress may lead to improved therapeutic interventions for the treatment of substance use disorders and mental illnesses.
    European Journal of Neuroscience 04/2014; 39(7). DOI:10.1111/ejn.12490 · 3.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In recent decades, major depression has become more prevalent and research has shown that immune activation and cytokine production may be involved. This review is mainly focused on the contribution of inflammation to depression. We first briefly introduce the inflammatory biomarkers of depression, then discuss the sources of cytokines in the brain, and finally describe the neuroimmunological mechanisms underlying the association between inflammation and depression.
    Neuroscience Bulletin 05/2014; 30(3). DOI:10.1007/s12264-013-1439-3 · 1.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Progress in medical technology, diagnostic procedures and imaging techniques results in a growing demand for well tolerated sedation regimens, devoid of respiratory and haemodynamic complications. Moreover, rapid turnover time dictates the need for rapid onset of effect and rapid recovery. Recent literature regarding the use of dexmedetomidine, ketamine and remifentanil for sedation outside the operating room is reviewed. As procedural sedation is often performed by nonanaesthesiologists, articles from journals other than anaesthesiology journals are also included. Dexmedetomidine seems an attractive choice for sedation, because of the lack of respiratory depression. It has been studied as a sole sedation agent or in combination with benzodiazepines or opioids. As premedication, it can be administered intranasally. Disadvantages are a rather slow onset and recovery. Bradycardia and hypotension are common. Ketamine got renewed attention mainly by nonanaesthesiologists performing procedural sedation. Psychogenic adverse effects and slow recovery limit its use. Psychiatrists are interested in its antidepressive effect. Ketamine has a potential role in lowering the risk of chronification of pain, modified by analgesic and anti-inflammatory effects. Remifentanil as an ultra-short-acting agent is less well studied outside the operating room. Its unique pharmacology permits its use in patient-controlled analgesia and sedation, in target-controlled infusion or in a combined technique. Recent literature is reviewed regarding dexmedetomidine, ketamine and remifentanil for its use outside the operating room. Sedationists have to keep in mind the pharmacokinetics and pharmacodynamics of the currently used agents in adults and children.
    Current opinion in anaesthesiology 04/2014; DOI:10.1097/ACO.0000000000000086 · 2.53 Impact Factor